Buy Chloroquine pills over the counter in online pharmacy

Product Name	Chloroquine
Dosage	Chloroquine phosphate 250 mg tablets (equivalent to 155 mg base)
Active Ingredient	Chloroquine (as chloroquine phosphate)
Form	Oral Tablets
Description	Prescription antimalarial used in the USA for chloroquine‑sensitive malaria prevention/treatment and certain amebic infections; not authorized for COVID‑19.
How to Order Without Prescription	Prescription required in the USA; telehealth evaluation available

Chloroquine is an established antimalarial medicine that has been used for decades and remains clinically relevant in certain settings in the United States. In the U.S., chloroquine is available by prescription only and is most commonly dispensed as chloroquine phosphate oral tablets, typically 250 mg (equivalent to 155 mg of chloroquine base). While hydroxychloroquine has largely replaced chloroquine for chronic autoimmune indications in U.S. practice, chloroquine still plays an important role for the prevention and treatment of malaria in regions where Plasmodium species remain sensitive to chloroquine and for select cases of extraintestinal (hepatic) amebiasis when combined with tissue‑active agents. If you are planning international travel or require therapy for a diagnosed infection, a licensed U.S. healthcare professional can determine whether Chloroquine is appropriate for you, provide a prescription, and outline dosing and monitoring tailored to your medical history. For safety, do not self‑medicate or use non‑prescribed antimalarials; professional guidance ensures correct dosing (expressed in base vs. salt), screening for drug interactions, and necessary ophthalmic and cardiac precautions.

Within the U.S., Chloroquine is dispensed in community and specialty pharmacies nationwide and through reputable mail‑order services. Generic formulations of chloroquine phosphate help reduce out‑of‑pocket costs for many patients who pay cash, and coverage through commercial insurance plans or public programs may further lower expenses depending on the indication and plan formulary. U.S. travel clinics and telehealth providers frequently coordinate malaria chemoprophylaxis for travelers to chloroquine‑sensitive regions such as certain parts of Central America, the Caribbean (e.g., Haiti and the Dominican Republic), and some Middle Eastern locales. Your clinician will review your itinerary, the CDC Yellow Book recommendations for your destination, and any contraindications (like preexisting retinal disease or arrhythmia risk) before issuing a prescription and counseling you on adherence, side‑effect recognition, and what to do if you miss a dose or develop symptoms abroad.

Chloroquine cost

In the USA, Chloroquine is available in generic form, which is usually significantly less expensive than any brand‑name equivalents. Total cost varies by pharmacy network, location, and whether you use insurance, a discount program, or pay cash. Because travel‑related prescriptions may be filled outside of insurance in some cases, many U.S. pharmacies provide transparent cash prices or discount cards for antimalarials. As a general orientation, the per‑tablet cash price for generic chloroquine phosphate 250 mg can range widely depending on supply dynamics, pharmacy margins, and negotiated discounts. Patients typically find the most value when obtaining the full course at once (for example, a multi‑week supply for prophylaxis that includes doses before, during, and after travel) since per‑unit pricing often becomes more favorable for larger quantities. Always verify the price with your chosen U.S. pharmacy prior to purchase and bring your prescription and ID to avoid delays.

When comparing costs, keep in mind that chloroquine dosing is conventionally expressed in milligrams of base, while U.S. tablets are labeled by the salt (chloroquine phosphate). A standard tablet of 250 mg chloroquine phosphate provides 155 mg of chloroquine base. This matters when calculating how many tablets you will need for prophylaxis or treatment. Your prescriber will specify both the tablet strength and the schedule in a way that clearly communicates how to take the medication. For travelers, the total number of tablets needed includes the startup dosing before arrival in the endemic region, weekly doses during the whole stay, and a continuation period after leaving the area, which can amount to several additional tablets depending on the trip length. Confirm the full quantity with your pharmacist to ensure you receive a complete course and avoid mid‑trip shortages.

Some U.S. pharmacies offer price‑matching or membership programs that reduce the cash price for common generic medications, including antimalarials. If affordability is a concern, ask your prescriber whether alternative chemoprophylaxis options (such as atovaquone‑proguanil or doxycycline) might be clinically appropriate and cost‑effective for your itinerary and health profile. Be sure to factor in not just the sticker price but also the dosing convenience, required duration, your potential side‑effect risks, and any drug–drug interactions with your current medicines. A travel‑medicine consultation can help you balance cost, convenience, and safety—especially if you have chronic conditions or take medications that could interact with Chloroquine.

For patients being treated in the USA for chloroquine‑sensitive malaria rather than using it for prevention, the total tablet count and cost structure differ from prophylaxis regimens. Treatment uses a loading dose followed by additional doses at specific intervals, and the exact number of tablets depends on the prescriber’s base‑equivalent schedule. It is important to fill the entire prescribed course in one visit and to take all doses as directed, even if you begin to feel better. Interrupting or under‑dosing malaria treatment can lead to treatment failure and complications. If cost or pharmacy access is an issue, discuss your situation with the prescribing clinician or pharmacist in advance so they can coordinate a practical and safe plan.

Where can I buy Chloroquine in the USA?

 In the United States, Chloroquine is a prescription medication and cannot be sold over‑the‑counter. To obtain it legally and safely, schedule a visit with your primary care provider, a travel‑medicine clinic, or a telehealth service licensed in your state. After a clinical assessment that includes a review of your travel itinerary or infection diagnosis, medical history, and current medication list, a U.S.‑licensed clinician can issue a prescription if Chloroquine is appropriate for you. You may then fill the prescription at your preferred local pharmacy or via a reputable U.S. mail‑order pharmacy that ships directly to your address.

Many travelers in the USA rely on telemedicine for malaria chemoprophylaxis prescriptions because it is fast, convenient, and specifically geared toward aligning with CDC recommendations for the destination. Telehealth services typically verify your identity, confirm your state of residence, and ensure that prescribing is compliant with U.S. federal and state regulations. They also provide counseling regarding when to start your medication, what to do if you miss a dose, which side effects to watch for, and when to seek urgent care during travel. If Chloroquine is not suitable due to resistance patterns at your destination or clinical considerations such as QT prolongation risk, your clinician will propose evidence‑based alternatives.

The combination of a legitimate U.S. prescription and a licensed pharmacy ensures that you receive authentic medication, appropriate dosing instructions, and patient support. Avoid purchasing antimalarials from unverified websites or international sources that bypass U.S. safety standards, as counterfeit or substandard medicines are a known global issue and can lead to treatment failure or serious harm. Reputable U.S. pharmacies and telehealth partners prioritize patient safety, confidentiality, and timely shipping ahead of travel; we encourage you to plan at least two weeks before departure so your consultation, prescription, and delivery are complete on time.

Chloroquine in the USA

Accessing Chloroquine in the U.S. is straightforward when you follow the proper clinical pathway. First, confirm whether your destination is chloroquine‑sensitive; if not, you will need a different prophylactic agent. Next, complete a travel consultation—either in‑person or via U.S. telehealth—during which you will discuss your medical history (including any heart rhythm disorders, retinal disease, psoriasis, porphyria, or liver issues), current medications, and allergies. If Chloroquine is appropriate, the prescriber will send an electronic prescription to your chosen U.S. pharmacy. From there, you can coordinate pick‑up or shipment. When used correctly and under medical supervision, Chloroquine offers a time‑tested option for malaria prevention and treatment in specific regions. Always carry your medication with you in your hand luggage, along with a copy of your prescription, and follow dosing exactly as prescribed.

What is chloroquine?

 Chloroquine is a 4‑aminoquinoline antimalarial agent that has been part of the global malaria armamentarium for many decades. In the USA, it is primarily used for the prevention and treatment of malaria caused by chloroquine‑sensitive Plasmodium species (including Plasmodium vivax, P. ovale, P. malariae, and some non‑resistant P. falciparum strains) and for select amebic infections when other agents are not suitable or as adjunctive therapy. Chloroquine is dispensed as chloroquine phosphate tablets; a commonly used strength is 250 mg (equivalent to 155 mg of chloroquine base), and dosing regimens are calculated in base equivalents. Your clinician will specify the exact schedule to ensure therapeutic levels are achieved for either prophylaxis or treatment.

Mechanistically, Chloroquine concentrates within the acidified food vacuoles of Plasmodium parasites and interferes with the detoxification of ferriprotoporphyrin IX (heme). By raising the vacuolar pH and inhibiting heme polymerase, chloroquine leads to accumulation of toxic heme, causing parasite death. For amebiasis, the drug contributes to parasite clearance in hepatic tissue, but tissue‑active agents (e.g., metronidazole or tinidazole) and a luminal amebicide are still required to fully eradicate the infection. Because chloroquine resistance is widespread among P. falciparum in many parts of the world, U.S. practice relies on current CDC maps and guidance to decide when it is appropriate for prophylaxis or treatment; otherwise, alternatives such as atovaquone‑proguanil, doxycycline, or mefloquine are selected.

In contemporary U.S. care, hydroxychloroquine (a related 4‑aminoquinoline) is generally preferred over chloroquine for chronic autoimmune conditions due to a more favorable safety profile with long‑term use, though Chloroquine retains clinical utility for malaria where sensitivity persists and for targeted infectious indications. Responsible prescribing includes patient education about dosing expressed in base versus salt, potential adverse effects (including rare but serious ocular and cardiac effects), interactions, and the necessity of follow‑up, particularly if travel plans change or if symptoms develop despite prophylaxis.

Chloroquine for Malaria Treatment

 In malaria treatment, Chloroquine is appropriate only when the infecting Plasmodium species is known or highly likely to be chloroquine‑sensitive, based on travel history and local resistance data. In the United States, clinicians typically confirm the species and parasitemia via diagnostic testing and then choose a treatment regimen aligned with CDC/IDSA guidance. Chloroquine dosing is stated in base equivalents, with a loading dose followed by additional doses at specified intervals to achieve adequate plasma levels. Adherence to the complete course is critical because partial treatment can lead to recrudescence or complications. In P. vivax and P. ovale infections, additional therapy with primaquine or tafenoquine may be required to eradicate hypnozoites and prevent relapse, pending G6PD status and other contraindications.

Symptoms of malaria can include fever, chills, malaise, headache, myalgias, and gastrointestinal upset; these may persist transiently even after effective therapy begins. Patients should be counseled on what to expect during recovery and advised to return for medical evaluation if fever persists, new neurologic symptoms arise, or if they experience signs of severe malaria such as altered mental status or respiratory distress. A follow‑up visit or call helps confirm clinical resolution. It is also prudent to discuss vector control measures (bed nets, repellents with DEET or picaridin, and protective clothing) since medication alone does not prevent mosquito bites or other vector‑borne infections that may coexist in endemic regions.

Because dosing errors can occur when converting between base and salt, U.S. prescriptions typically include both units (e.g., chloroquine base target dose with the corresponding chloroquine phosphate tablet count). Pharmacists routinely verify dosing appropriateness—especially for children, for whom weight‑based dosing applies—and can provide medication guides that show exactly how many tablets to take per dose and at what time intervals. Whenever Chloroquine is prescribed, it is essential to review the patient’s current medications to screen for potential QT prolongation or other interactions that could increase side‑effect risks during therapy.

The importance of chloroquine in malaria care

Although resistance has curtailed the global use of Chloroquine for P. falciparum in many regions, chloroquine remains a safe and effective option where sensitivity persists and for non‑falciparum species. Its long track record, weekly prophylaxis schedule, and generally good tolerability when used short‑term make it a useful choice for suitable itineraries and patient profiles. In addition, the clarity of dosing schedules and widespread U.S. availability of generic tablets allow for predictable planning before travel. The key is proper selection of candidates, considering destination‑specific resistance data, personal cardiac and ophthalmologic risk factors, and concomitant medications. Shared decision‑making with a U.S. travel‑medicine provider ensures that Chloroquine is used where it is likely to be effective and safe, and that alternatives are selected when resistance or safety concerns dictate.

Chloroquine and COVID‑19 in the USA

 Early in the COVID‑19 pandemic, chloroquine and hydroxychloroquine were studied for potential antiviral effects. Subsequent robust clinical trials and U.S. regulatory assessments found no proven benefit for prevention or treatment of COVID‑19 and identified safety concerns, particularly regarding cardiac arrhythmias when combined with other QT‑prolonging agents. The U.S. Food and Drug Administration (FDA) revoked the Emergency Use Authorization for these agents in COVID‑19, and major U.S. guidelines (NIH, IDSA) recommend against their use for COVID‑19 outside of clinical trials. Patients in the USA should not use Chloroquine for COVID‑19 and should consult a clinician for evidence‑based therapies and vaccinations recommended by current U.S. public health guidance.

Is chloroquine antiviral?

Chloroquine exhibits in‑vitro activity that can affect viral replication pathways and endosomal pH; however, in‑vitro findings do not translate into clinical efficacy for COVID‑19, and high‑quality trials in humans have not shown benefit. In the U.S., Chloroquine should be reserved for approved and evidence‑supported indications such as chloroquine‑sensitive malaria and certain amebic infections. Using chloroquine off‑label for viral illnesses without clinician oversight can expose patients to avoidable risks, including dangerous cardiac effects, drug interactions, and delays in receiving effective care.

Chloroquine and autoimmune conditions

 In U.S. practice, hydroxychloroquine is usually preferred over chloroquine for chronic autoimmune indications such as systemic lupus erythematosus and rheumatoid arthritis due to a more favorable long‑term safety profile. While chloroquine has historical use in autoimmune disease, its routine use for these conditions in the USA has decreased. Patients already stabilized on hydroxychloroquine should not switch to Chloroquine without a compelling clinical reason and specialist supervision. Any consideration of chloroquine for autoimmune disease in the USA should involve a rheumatologist or relevant specialist who can weigh risks and benefits, arrange baseline and periodic ophthalmologic exams, and monitor for systemic adverse effects.

Chloroquine for Amebiasis

 For extraintestinal amebiasis (e.g., amebic liver abscess), Chloroquine may be used as adjunctive therapy in combination with tissue‑active agents like metronidazole or tinidazole, followed by a luminal amebicide to eradicate intraluminal organisms. Monotherapy with chloroquine is inadequate for complete cure. U.S. clinicians tailor regimens based on disease severity, imaging findings, and patient comorbidities. Because dosing regimens and durations can vary, patients should not self‑treat suspected amebiasis; instead, seek medical evaluation and adhere strictly to the prescribed combination regimen to ensure full eradication and to prevent relapse or complications.

Action

 Chloroquine exerts antimalarial activity by concentrating within the parasite’s acidic food vacuole and disrupting heme detoxification. The accumulation of toxic heme leads to oxidative damage and parasite death. This pharmacodynamic effect depends on adequate plasma and tissue concentrations, which are achieved through weight‑appropriate dosing in base equivalents. The drug’s long terminal half‑life supports weekly prophylaxis schedules for eligible travelers. In hepatic amebiasis, chloroquine contributes to tissue parasite clearance but must be paired with appropriate companion agents to achieve a microbiologic cure.

From a pharmacologic standpoint, chloroquine has a narrow therapeutic window, and toxicity risk increases with overdosing or accidental ingestion by children. Its safety profile is generally acceptable for short‑term prophylaxis in appropriate candidates, but clinicians remain vigilant for rare yet serious adverse events, including retinopathy (risk rises with cumulative exposure), cardiomyopathy, QT prolongation, hypoglycemia, and neuropsychiatric effects. Because these risks are modulated by dose, duration, comorbid conditions, and interacting medications, U.S. prescribers and pharmacists emphasize careful medication reconciliation and patient education at the time of prescribing.

Safety

Millions of patients worldwide have received chloroquine for malaria prevention or treatment. In the USA, when Chloroquine is used appropriately for short‑term prophylaxis or acute therapy, most adverse effects are mild and transient (e.g., gastrointestinal upset, headache, pruritus, or insomnia). Nonetheless, all patients should be counseled about serious but uncommon risks. Of particular concern are retinal toxicity with prolonged or high cumulative dosing, hypoglycemia (sometimes severe), cardiomyopathy, and QT interval prolongation that can precipitate arrhythmias in susceptible individuals. These risks underscore the importance of a legitimate U.S. prescription, baseline risk assessment, and avoidance of unnecessary off‑label use.

Chloroquine is metabolized hepatically and may accumulate in tissues including the retina and myocardium with long‑term exposure. In short‑term use for malaria prophylaxis or treatment, clinically significant accumulation is less likely, but caution remains prudent in patients with preexisting retinal disease, cardiac conduction abnormalities, liver dysfunction, psoriasis, or porphyria. Patients should report visual changes, palpitations, syncope, severe dizziness, or neuropsychiatric symptoms immediately. U.S. clinicians commonly advise taking Chloroquine with food to reduce gastrointestinal upset and spacing it away from antacids or kaolin to avoid decreased absorption.

Chloroquine dosage for humans

 Dosing for Chloroquine is conventionally specified in milligrams of chloroquine base, though U.S. tablets are labeled as chloroquine phosphate salt. A 250 mg chloroquine phosphate tablet contains 155 mg of base. Your U.S. prescriber will calculate an appropriate regimen based on indication (treatment vs. prophylaxis), age, weight (particularly in pediatrics), destination resistance patterns, and your medical history. For malaria, exact timing and total dose are important to achieve therapeutic concentrations and to minimize the risk of side effects. Never exceed the prescribed dose, and keep Chloroquine out of reach of children due to the serious consequences of accidental ingestion.

To minimize gastrointestinal discomfort, Chloroquine may be taken with food or milk. If you vomit soon after a dose, contact your clinician for advice—an extra dose may be recommended in certain situations. Do not double dose without guidance. Because base‑equivalent calculations can be confusing, ask your pharmacist to write your schedule in plain tablet counts (“take X tablets at each dose”) and to clarify how the salt strength relates to the base dose. This avoids dosing errors and helps you follow your U.S. clinician’s instructions precisely.

Dosing for travel chemoprophylaxis

 For eligible itineraries in chloroquine‑sensitive regions, U.S. travel‑medicine guidance typically recommends starting Chloroquine one to two weeks before travel, continuing once weekly during travel, and for four weeks after leaving the malaria‑endemic area. The prescribed dose is weight‑based for children and a standard base‑equivalent weekly dose for most adults, given as the corresponding number of chloroquine phosphate tablets. Take the weekly dose on the same day each week. If you miss a dose, take it as soon as possible and then return to your regular schedule. Because timing and adherence directly affect protection, build reminders into your travel routine and pack enough tablets to cover unexpected delays or itinerary changes.

Use the higher end of the dosage range in the following cases:

• when clinical guidance specifies weight‑based adjustments in heavier adults to ensure adequate base‑equivalent exposure
  
• if your prescriber advises a loading strategy before imminent departure to reach steady‑state levels on time
  
• in travelers with complex itineraries or extended stays where prophylaxis must be maintained across multiple exposure windows, as directed by a clinician

Chloroquine dosing for malaria treatment (chloroquine‑sensitive)

The adult treatment regimen in the USA is commonly expressed in chloroquine base equivalents, administered as chloroquine phosphate tablets according to a loading dose followed by additional doses at 6, 24, and 48 hours. Pediatric dosing is weight‑based and carefully calculated to avoid toxicity while achieving therapeutic levels. Because dosing details are individualized and may vary based on species and patient factors, follow the exact schedule on your prescription label and pharmacist’s instructions. Your clinician may order follow‑up testing to assess clinical response and to determine if additional therapy (such as primaquine for P. vivax or P. ovale hypnozoites) is needed. Seek urgent care if severe symptoms persist or worsen.

Chloroquine dosing for malaria chemoprophylaxis

For U.S. travelers to chloroquine‑sensitive regions, the standard approach is a once‑weekly base‑equivalent dose of Chloroquine, starting 1–2 weeks before arrival, continuing weekly during the stay, and for four weeks after departure. Children receive weight‑based weekly dosing. Take each weekly dose on the same weekday to establish a consistent routine. If your itinerary changes, consult your clinician about adjusting the total number of tablets so you do not run short. Prophylaxis reduces but does not eliminate the risk of malaria; continue to practice insect precautions and seek medical evaluation promptly if you develop fever during or after travel.

How to take chloroquine

 Take Chloroquine exactly as prescribed by your U.S. clinician. Swallow the tablets with a full glass of water, preferably with food to reduce stomach upset. Avoid taking the medication at the same time as antacids or kaolin‑containing products because they can decrease chloroquine absorption; separate administration by several hours. If you miss a weekly prophylaxis dose, take it as soon as you remember, then resume your usual schedule. Do not take extra tablets to make up for a missed dose without your clinician’s advice.

For acute malaria treatment, adhere closely to the timed dosing schedule. If vomiting occurs soon after a dose, contact your prescriber; a replacement dose may be needed. Maintain hydration and rest, and arrange follow‑up to confirm recovery. If you are prescribed additional agents (e.g., primaquine) to prevent relapse in P. vivax or P. ovale, ensure you complete the entire course as instructed. Keep Chloroquine in its original container, at room temperature, away from moisture and out of the reach of children.

Pregnancy and breastfeeding

When used at recommended doses for malaria prophylaxis or treatment, Chloroquine is generally considered acceptable during pregnancy in the USA for chloroquine‑sensitive regions and infections. Because malaria poses significant risks to pregnant individuals and their fetuses, U.S. clinicians carefully select preventive regimens based on destination and safety data. For breastfeeding, only small amounts of chloroquine enter breast milk and are not enough to protect the infant; infants who require prophylaxis must receive their own age‑ and weight‑appropriate regimen. Always review pregnancy or breastfeeding status with your clinician so that the most suitable, evidence‑based option is chosen.

Pharmacist’s tips for taking chloroquine

 To decrease gastrointestinal side effects, take Chloroquine with food or milk and at the same time on scheduled days. Use reminders or a travel calendar to maintain adherence. If you experience significant nausea, your clinician may recommend supportive measures or adjust the timing to improve tolerability.

For malaria prophylaxis, begin Chloroquine 1–2 weeks prior to entering an endemic area to ensure therapeutic levels, continue weekly during travel, and complete four weeks after leaving. Even with medication, use insect avoidance measures (treated bed nets, long sleeves, and repellents with DEET or picaridin) for comprehensive protection.

Because Chloroquine can interact with drugs that prolong the QT interval or that alter its absorption or metabolism, give your pharmacist a complete and up‑to‑date list of all prescription drugs, over‑the‑counter medications, vitamins, and herbal supplements. Ask specifically about antacids, heart rhythm medications, and antibiotics known to affect the QT interval.

If you notice visual disturbances (blurred vision, difficulty focusing, changes in color vision), palpitations, fainting, severe dizziness, or symptoms of hypoglycemia (sweating, confusion, tremors), seek medical attention promptly. Store Chloroquine securely—accidental ingestion can be dangerous, especially for children.

Safety Precautions

 Do not use Chloroquine if you have a known hypersensitivity to chloroquine or any component of the formulation. Inform your clinician if you have a history of retinal disease, significant cardiac disease (including known QT prolongation), porphyria, psoriasis, liver disease, seizure disorders, or severe glucose regulation issues, as these may influence the choice of prophylaxis or treatment.

Avoid alcohol excess while taking Chloroquine, as it may worsen dizziness or gastrointestinal side effects and can complicate glucose control. Separate doses from antacids or kaolin to ensure adequate absorption, and do not exceed the prescribed amount—chloroquine has a narrow therapeutic window.

Use Chloroquine with caution if you take other QT‑prolonging medications. Baseline ECG and electrolyte assessment may be recommended for patients with additional risk factors. For long‑term or repeated use, your clinician may arrange ophthalmologic monitoring to mitigate the risk of retinal toxicity.

Chloroquine side effects

 Most side effects are mild and self‑limited, including nausea, abdominal discomfort, headache, pruritus (itching), dizziness, and sleep disturbances. Itching can be more common in some populations and during active malaria illness. Taking Chloroquine with food often improves gastrointestinal tolerability. If you experience persistent or bothersome symptoms, contact your clinician for guidance.

Serious adverse reactions are uncommon with short‑term prophylaxis or treatment but can occur. These include hypoglycemia (sometimes severe), cardiomyopathy, QT prolongation and arrhythmias, neuropsychiatric effects (such as agitation, confusion, or seizures), and retinal toxicity (risk increases with higher cumulative doses and prolonged use). Immediate medical evaluation is warranted if you develop visual changes, chest pain, palpitations, syncope, severe dizziness, or signs of severe hypoglycemia.

Laboratory abnormalities may include transient changes in liver enzymes or blood counts. Your clinician may order labs if you have underlying hepatic conditions or if symptoms suggest an adverse reaction. Side‑effect profiles can vary by indication, duration of therapy, and co‑administered medications, which is why individualized counseling before starting Chloroquine is essential.

Symptoms by Infection Type

During malaria treatment with Chloroquine, possible side effects include:

• unusual weakness
• loss of appetite, abdominal pain, constipation or diarrhea
• nausea or vomiting
• drowsiness or dizziness
• anxiety
• decreased white blood cell count
• anemia (reduced red blood cells)

For patients treated for amebic liver abscess or acute malaria, symptoms may include:

• sweating or fever
• headache
• unusual weakness
• muscle and joint pain or body aches
• loss of appetite, nausea
• upper or lower abdominal pain
• cough or sore throat
• shortness of breath
• low blood pressure
• fainting or dizziness when standing
• chills
• dizziness

In travelers recovering from malaria, the following effects can occur:

• itching that may persist or intensify temporarily as the infection resolves.

Seek medical attention urgently if you experience any of the following warning signs while using Chloroquine:

• itching or rash
• joint or muscle pain
• fever
• nausea or vomiting
• inflamed lymph nodes
• swelling of hands, ankles, or feet
• diarrhea
• dizziness
• low blood pressure
• fainting when standing
• rapid heartbeat
• headache or fatigue
• vision problems such as eye pain, redness, increased sensitivity to light,
  changes in color vision or blurred vision,
  new or worsening breathing issues

Reporting side effects

 If you experience any side effects, contact your U.S. clinician or pharmacist. You can also report adverse events to the FDA MedWatch program. This includes any side effects not listed in this guide. Prompt reporting helps clinicians optimize your care and contributes to medication safety monitoring nationwide.

Interaction of chloroquine with other medicines

 Chloroquine can interact with certain medications and supplements. Always provide your U.S. clinician and pharmacist with a complete list of all prescription drugs, over‑the‑counter medicines, vitamins, and herbal products you take. Some interactions may increase the risk of serious side effects (such as arrhythmias) or reduce Chloroquine absorption or efficacy. Your care team can typically prevent or manage interactions through dose adjustments, scheduling changes, or by selecting alternative therapies when appropriate.

Some medicines that may interact with chloroquine include:

• antiarrhythmics and other QT‑prolonging agents (e.g., amiodarone, sotalol)
  
• macrolide antibiotics (e.g., azithromycin, clarithromycin)
  
• fluoroquinolone antibiotics (e.g., ciprofloxacin, levofloxacin)
  
• antacids or kaolin products that reduce absorption (separate dosing times)
  
• warfarin and other anticoagulants (monitor INR as advised)
  

This list is not exhaustive. Keep a detailed, up‑to‑date list of all medicines you take and share it with your U.S. clinician and pharmacist to minimize the risk of harmful drug interactions. Do not start or stop any medication while taking Chloroquine without medical advice.

Recommendations from our specialists

 If you are traveling from the USA to a malaria‑endemic area, plan ahead. Book a travel‑medicine consultation 4–6 weeks before departure to confirm whether your destination is chloroquine‑sensitive and to secure an appropriate prescription, vaccination guidance, and insect‑avoidance strategies. If Chloroquine is prescribed, verify your pharmacy fill well before departure to allow time for delivery or pickup, and carry your medication in your hand luggage alongside your prescription. For acute treatment of chloroquine‑sensitive malaria or adjunctive amebiasis care, follow your clinician’s instructions exactly and complete all components of therapy. Using licensed U.S. providers and pharmacies ensures authentic medication, correct dosing, and safety monitoring aligned with CDC guidance.

Ready to Protect Your Health? Order Chloroquine in the USA

Travel with confidence by arranging a U.S. prescription for Chloroquine when indicated, and have your tablets dispensed by a licensed U.S. pharmacy with fast, discreet shipping. Our platform connects you to reputable services that prioritize safety, authenticity, and timely delivery so you can focus on your trip and health.

• Prescription support — consult U.S.‑licensed clinicians via telehealth or in‑person as appropriate
  
• Fast, secure shipping within the United States and to eligible U.S. addresses
  
• Genuine medication dispensed by licensed U.S. pharmacies
  
• Competitive pricing on generics with clear dosing in base and salt equivalents
  
• Expert customer support to help with refills, timing, and travel questions
  

Thousands of U.S. travelers and patients rely on evidence‑based prescribing for malaria prevention and treatment. Prepare early, follow your clinician’s instructions, and keep Chloroquine secure while traveling. Safe journeys start with informed, proactive care.

Buy Chloroquine Now